Comparison of adherence between twice- and thrice-daily regimens of oral amoxicillin/clavulanic acid

Respirology

Volumn 17, Issue 4, 2012, Pages 687-692

  Llor, Carl ^a   Bayona, Carolina ^b   Hernández, Silvia ^c   Moragas, Ana ^c   Miravitlles, Marc ^d  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b Primary Care Centre Valls Urbà   (Spain)

^c Primary Care Centre Jaume I   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

amoxicillin potassium clavulanate combination; drug administration schedule; micro electrical mechanical system; patient compliance; respiratory tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PHARYNGITIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TOOTH INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLAVULANIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARYNGITIS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS;

EID: 84859918888     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02159.x     Document Type: Article

References (21)

1. Haynes RB, Ackloo E, Sahota N, et al,. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. 2008; (2): CD000011.
2. Sclar DA, Tartaglione TA, Fine MJ,. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect. Agents Dis. 1994; 3: 266-73. (Pubitemid 24367062)
3. Vrijens B, Urquhart J,. Patient adherence to prescribed antimicrobial drug dosing regimens. J. Antimicrob. Chemother. 2005; 55: 616-27. (Pubitemid 40691838)
4. Osterberg L, Blaschke T,. Adherence to medication. N. Engl. J. Med. 2005; 353: 487-97. (Pubitemid 41127293)
5. Kardas P, Devine S, Golembesky A, et al,. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int. J. Antimicrob. Agents 2005; 26: 106-13. (Pubitemid 41021961)
6. Llor C, Sierra N, Hernández S, et al,. The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the adherence. J. Antimicrob. Chemother. 2009; 63: 386-9.
7. Kaye CM, Allen A, Perry S, et al,. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 2001; 23: 578-84. (Pubitemid 32411408)
8. Sethi S, Breton J, Wynne B,. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 2005; 49: 153-60.
9. File TM Jr, Lode H, Kurz H, et al,. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin- clavulanate (2000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2004; 48: 3323-31. (Pubitemid 39129326)
10. Petitpretz P, Chidiac C, Soriano F, et al,. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int. J. Antimicrob. Agents 2002; 20: 119-29. (Pubitemid 35286529)
11. Damrikamiert L, Jauregui AC, Kzadri M,. Efficacy and safety of amoxycillin/clavulanate (Augmentin) twice daily versus three times daily in the treatment of acute otitis media in children. The Augmentin 454 Study Group. J. Chemother. 2000; 12: 79-87. (Pubitemid 30139832)
12. Cals JW,. Comment on: the higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. J. Antimicrob. Chemother. 2009; 63: 1083-4.
13. Garau J, Twynholm M, Garcia-Mendez E, et al,. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J. Antimicrob. Chemother. 2003; 52: 826-36. (Pubitemid 37407812)
14. Urquhart J,. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad. Med. J. 1992; 68 (Suppl. 3): S69-78.
15. Craig WA,. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 1998; 26: 1-10.
16. Drusano GL, Craig WA,. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. 1997; 9 (Suppl. 3): 38-44. (Pubitemid 27294747)
17. Thomas JK, Forrest A, Bhavnani SM, et al,. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 1998; 42: 521-7. (Pubitemid 28114802)
18. Andes D,. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr. Opin. Infect. Dis. 2001; 14: 165-72. (Pubitemid 32232987)
19. Favre O, Delacrétaz E, Badan M, et al,. Relationship between the prescriber's instructions and compliance with antibiotherapy in outpatients treated for an acute infectious disease. J. Clin. Pharmacol. 1997; 37: 175-8. (Pubitemid 27163558)
20. Hawkings NJ, Cutler CC, Wood F,. Antibiotics in the community: a typology of user behaviours. Patient Educ. Couns. 2008; 73: 146-52.
21. Murio C, Soler X, Pérez M, et al,. Acute exacerbations of chronic obstructive pulmonary disease in primary care in Spain: the EPOCAP study. Ther. Adv. Respir. Dis. 2010; 4: 215-23.